Utilizing neurodegenerative markers for the diagnostic evaluation of amyotrophic lateral sclerosis
© 2024. The Author(s)..
BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive deterioration of upper and lower motor neurons. A definitive diagnostic test or biomarker for ALS is currently unavailable, leading to a diagnostic delay following the onset of initial symptoms. Our study focused on cerebrospinal fluid (CSF) concentrations of clusterin, tau protein, phosphorylated tau protein, and beta-amyloid1-42 in ALS patients and a control group.
METHODS: Our study involved 54 ALS patients and 58 control subjects. Among the ALS patients, 14 presented with bulbar-onset ALS, and 40 with limb-onset ALS. We quantified biomarker levels using enzyme-linked immunosorbent assay (ELISA) and compared the results using the Mann-Whitney U-test.
RESULTS: Significant elevations in neurodegenerative markers, including tau protein (p < 0.0001), phosphorylated tau protein (p < 0.0001), and clusterin (p = 0.038), were observed in ALS patients compared to controls. Elevated levels of tau protein and phosphorylated tau protein were also noted in both bulbar and limb-onset ALS patients. However, no significant difference was observed for beta-amyloid1-42. ROC analysis identified tau protein (AUC = 0.767) and p-tau protein (AUC = 0.719) as statistically significant predictors for ALS.
CONCLUSION: Our study demonstrates that neurodegenerative marker levels indicate an ongoing neurodegenerative process in ALS. Nonetheless, the progression of ALS cannot be predicted solely based on these markers. The discovery of a specific biomarker could potentially complement existing diagnostic criteria for ALS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
European journal of medical research - 29(2024), 1 vom: 06. Jan., Seite 31 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Klíčová, Kateřina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Amyotrophic lateral sclerosis |
|---|
| Anmerkungen: |
Date Completed 08.01.2024 Date Revised 09.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s40001-023-01596-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366752391 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366752391 | ||
| 003 | DE-627 | ||
| 005 | 20240114233122.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s40001-023-01596-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1253.xml |
| 035 | |a (DE-627)NLM366752391 | ||
| 035 | |a (NLM)38184629 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Klíčová, Kateřina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Utilizing neurodegenerative markers for the diagnostic evaluation of amyotrophic lateral sclerosis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.01.2024 | ||
| 500 | |a Date Revised 09.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive deterioration of upper and lower motor neurons. A definitive diagnostic test or biomarker for ALS is currently unavailable, leading to a diagnostic delay following the onset of initial symptoms. Our study focused on cerebrospinal fluid (CSF) concentrations of clusterin, tau protein, phosphorylated tau protein, and beta-amyloid1-42 in ALS patients and a control group | ||
| 520 | |a METHODS: Our study involved 54 ALS patients and 58 control subjects. Among the ALS patients, 14 presented with bulbar-onset ALS, and 40 with limb-onset ALS. We quantified biomarker levels using enzyme-linked immunosorbent assay (ELISA) and compared the results using the Mann-Whitney U-test | ||
| 520 | |a RESULTS: Significant elevations in neurodegenerative markers, including tau protein (p < 0.0001), phosphorylated tau protein (p < 0.0001), and clusterin (p = 0.038), were observed in ALS patients compared to controls. Elevated levels of tau protein and phosphorylated tau protein were also noted in both bulbar and limb-onset ALS patients. However, no significant difference was observed for beta-amyloid1-42. ROC analysis identified tau protein (AUC = 0.767) and p-tau protein (AUC = 0.719) as statistically significant predictors for ALS | ||
| 520 | |a CONCLUSION: Our study demonstrates that neurodegenerative marker levels indicate an ongoing neurodegenerative process in ALS. Nonetheless, the progression of ALS cannot be predicted solely based on these markers. The discovery of a specific biomarker could potentially complement existing diagnostic criteria for ALS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Amyotrophic lateral sclerosis | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a Cerebrospinal fluid | |
| 650 | 7 | |a Clusterin |2 NLM | |
| 650 | 7 | |a tau Proteins |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Mareš, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Menšíková, Kateřina |e verfasserin |4 aut | |
| 700 | 1 | |a Kaiserová, Michaela |e verfasserin |4 aut | |
| 700 | 1 | |a Friedecký, David |e verfasserin |4 aut | |
| 700 | 1 | |a Kaňovský, Petr |e verfasserin |4 aut | |
| 700 | 1 | |a Strnad, Miroslav |e verfasserin |4 aut | |
| 700 | 1 | |a Matěj, Radoslav |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of medical research |d 1998 |g 29(2024), 1 vom: 06. Jan., Seite 31 |w (DE-627)NLM090122402 |x 2047-783X |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2024 |g number:1 |g day:06 |g month:01 |g pages:31 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s40001-023-01596-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2024 |e 1 |b 06 |c 01 |h 31 | ||